PJ007
2 days ago
This is also from the same company (Biosynth)website: Interesting…,
ZYB09599
Brilacidin tetrahydrochloride
Brilacidin tetrahydrochloride is an analog of a naturally occurring peptide that has been shown to have anticancer properties. It works by inhibiting the activity of kinases, which are enzymes that play a critical role in cancer cell growth and survival. Brilacidin tetrahydrochloride has been shown to induce apoptosis, or programmed cell death, in tumor cells. In addition to its anticancer effects, this compound also has potential as an inhibitor of protein kinase C (PKC), which is involved in a variety of signaling pathways. Brilacidin tetrahydrochloride has been studied in Chinese hamster ovary cells and human urine samples, and it shows promising results as a potential anticancer agent. It may also have potential therapeutic applications for other diseases such as dabigatran-induced nephropathy.
SitTight
2 days ago
I think they are refering to it in regards to Brilacidin beeing a AMP/HDP.
Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs) https://pubchem.ncbi.nlm.nih.gov/compound/Brilacidin
So what's AMP/HDPs good for?
Antimicrobial peptides (AMPs) and host defense peptides (HDPs) are examples of membrane-active compounds with enhanced affinity for the negatively charged prokaryotic membranes with strong electrical potential gradients as prerequisites for cellular entry or direct disruption of the bacterial cell membrane. (6,7) These peptides are the first line of defense in many multicellular organisms and possess a broad range of biological activities, including antibacterial, antifungal, antiviral, anticancer, antiplasmodial, antiprotistal, insecticidal, spermicidal, and immunomodulatory activities.
Despite so many advantages, peptide antibiotics have had relatively little clinical success largely due to their in vivo toxicity, limited bioavailability, and large production costs. https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.2c00684
Not so with Brilacidin with its low toxidity and cheap production costs. I really hope at some point Brilacidin's huge scientific bofy of evidence will eventually overpower the massive incompetence of our CEO.
sunspotter
5 days ago
I think Ehrlich has mentally shuttered IPIX, and is waiting expectantly for the inevitable SEC suspension and subsequent delisting.
As IPIX is a limited company he will have no personal liability for the approximately $1.5 million owed to Cummings, and he will use the resulting bankruptcy to explain why shareholders receive nothing once the company is wound up (shareholders are always bottom of the list, behind even the employees whose improvident actions (that's being polite) caused the bankruptcy).
He will hope avidly and probably successfully that no one ever really follows the money, particularly his shark-jumping gift of $4 million to an off-shore private company and the issue of millions of cheap shares to his Aspire and Kips' Bay buddies.
It's penny stock grifting 101, and IPIX isn't Leo's first rodeo.
loanranger
5 days ago
Were the Directors foolish to resign? Will CEO Leo Ehrlich ever be heard from again?
Will these be the last words the public ever hears from this Company?
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 31, 2024, Barry Schechter and Zorik Spektor each resigned from the Board of Directors of Innovation Pharmaceuticals Inc. (the “Company”), effective immediately. Their decisions to resign were not the result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices.
Item 8.01 Other Events.
As previously disclosed, on January 22, 2020, the Company filed a complaint against Cummings Properties, LLC (“Cummings”) in the Superior Court of the Commonwealth of Massachusetts (C.A. No. 20-77CV00101), seeking, among other things, declaratory relief that the lease relating to the Company’s prior principal executive offices terminated in September 2018 rather than automatically extending for an additional five years. On August 29, 2023, the trial for this case commenced, and on January 18, 2024, the Court ruled in favor of Cummings, finding that Cummings is entitled to recover liquidated damages in the amount of $810,251.36, minus the Company’s $77,600 security deposit, plus eighteen percent per annum interest owing since January 17, 2020. The Company intends to appeal the decision.
The End?
zandant
5 days ago
Maybe the recluse, Lost It All Leo, can do a Google Search press release. This debacle is an absolute disaster. If Brilacidin was as great as you believe it to be, this pile of junk would not be on life support. And given Error Prone Ehrlich's track record, I seriously doubt BeaMed will pull Ehrlich out of the sewer. If BeaMed is a great as you believe it to be, why would the Laser Boys sell such a large percentage to the idiot for $4 million - a lot for cash-strapped Ehrlich in a move that left his company with no funds but a pittance if the Laser Boys believed their product was a blockbuster. Doubt the Laser Boy would be so stupid. "A fool and his money......" Your IPIX portfolio must look like a nuclear bomb went off.